Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8873 - 8880 of 12091 results

Regulation Crowdfunding: The Long Wait Is Over, But Is Equity Crowdfunding D.O.A.?
December 8, 2015| Alert| Viewpoint

The Twenty-Year Ascendancy of Health Care Qui Tam Litigation in Five Simple Graphs
December 8, 2015| Advisory| Viewpoint

Choosing Sides in a Divorce: Does it Apply to Employers Too? NJ Supreme Court Weighing Contours of “Marital Status” Discrimination
December 8, 2015| Blog| Viewpoint

Post Paris and San Bernardino Attacks: Visa Policies Under More Scrutiny
December 8, 2015| Blog| Viewpoint

Safe Harbor Negotiations Post-Paris
December 8, 2015| Blog| Viewpoint

Que Certa, Certa: Supreme Court Creates Uncertainty with "Cert" Review of Puerto Rico Recovery Act
December 8, 2015| Blog| Viewpoint

DOJ Recovers $3.5 Billion in False Claims Act Cases in FY2015 and Pays Record Amount to Qui Tam Relators
December 8, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
